MNMichał Niedziela

Michał Niedziela

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michał Niedziela has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pediatric inflammatory bowel disease: a review of current research

    by Alina Mykhalevych, Julia Anna Grygorowicz, Monika Sas-Wyżykowska, Aliaksandr Kryshtofik, Michał Niedziela, Monika Maruszak, Akhil Roy Subramoney, Anna Wyżykowska, Aleksandra Blachucik, Gabriela Faria

    Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis, is a growing global health challenge, with approximately 25% of cases diagnosed before the age of 20. These chronic immune- mediated disorders result from complex interactions between genetic predisposition, environmental triggers, gut microbiome alterations, and immune dysregulation. Pediatric IBD presents with more extensive disease than adult-onset cases, with unique manifestations including growth failure and delayed puberty. Diagnosis relies on clinical assessment, fecal calprotectin, and endoscopic evaluation. Contemporary management emphasizes treat-to-target strategies using exclusive enteral nutrition (60–80% remission rates) and biologic therapies for moderate- to-severe disease. Anti-TNF agents remain first-line biologics, while ustekinumab has recently received Food and Drug Administration and European Medicines Agency approvals for pediatric CD based on the UNITI Jr trial, and emerging data on JAK inhibitors further expand the therapeutic landscape. This review provides a comprehensive overview of disease subtypes, pathophysiology, diagnostics, and evidence-based treatment strategies.

  • Open Access

    Gut microbiota in multiple sclerosis: immunological mechanisms and therapeutic implications

    by Michał Niedziela, Monika Maruszak, Anna Wyżykowska, Julia Grygorowicz, Gabriela Faria, Alina Mykhalevych, Monika Sas-Wyżykowska, Aleksandra Blachucik, Aliaksandr Kryshtofik

    Multiple sclerosis is a chronic autoimmune disorder characterised by inflammation, demyelination, and progressive neurodegeneration within the central nervous system. In recent years, increasing attention has been directed towards the potential role of the gut microbiota in the pathogenesis of multiple sclerosis. Intestinal microorganisms interact with the immune system and may influence neuroinflammatory processes through the gut–brain axis. Growing evidence suggests that disturbances in gut microbial composition may contribute to the immune dysregulation observed in patients with multiple sclerosis. The aim of this narrative review is to summarise current knowledge regarding alterations in gut microbiota composition in individuals with multiple sclerosis, as well as to discuss the immunological mechanisms linking intestinal microorganisms with disease development. A comprehensive literature search was performed using the PubMed, Scopus, and Web of Science databases. Studies addressing gut microbiota, immune mechanisms, and microbiota-targeted therapeutic strategies in multiple sclerosis were analysed and synthesised. Available evidence indicates that patients with multiple sclerosis often present alterations in gut microbial composition, including reduced abundance of beneficial commensal bacteria and increased representation of pro-inflammatory taxa. These changes may influence immune responses through mechanisms involving T-cell differentiation, cytokine signalling, and microbial metabolite production. Experimental and clinical studies also suggest that microbiota-targeted interventions, such as probiotic supplementation or modulation of microbial metabolites, including short-chain fatty acids, may affect inflammatory pathways involved in multiple sclerosis. Although current clinical evidence remains limited, a growing body of research indicates that modulation of the gut microbiota may represent a promising complementary strategy in the management of multiple sclerosis.

  • Open Access

    DEXMEDETOMIDINE FOR SEDATION IN CHILDREN – A NARRATIVE REVIEW OF CLINICAL EVIDENCE, SAFETY CONSIDERATIONS, AND EMERGING THERAPEUTIC ROLES

    by Gabriela Faria, Anna Wyżykowska, Monika Maruszak, Julia Grygorowicz, Michał Niedziela, Monika Sas-Wyżykowska, Alina Mykhalevych, Aliaksandr Kryshtofik, Aleksandra Blachucik

    Dexmedetomidine is a highly selective alfa2-adrenergic agonist increasingly used in pediatric anesthesia and intensive care because of its unique sedative profile and minimal respiratory depressive effects. This narrative summarizes current evidence regarding the pharmacology, pharmacokinetics, clinical efficacy, safety profile and emerging applications of dexmedetomidine in pediatric patients. Current literature supports the use of dexmedetomidine in multiple clinical settings, including procedural sedation, perioperative management, and pediatric intensive care. The drug has demonstrated efficacy in reducing opioid requirements, preventing emergence agitation and delirium, and providing effective sedation while preserving spontaneous respiration. However, its use remains associated with dose-dependent cardiovascular adverse effects, particularly bradycardia and hypotension, requiring individualized dosing and careful monitoring, especially in neonates and infants due to age-related pharmacokinetic variability. Emerging evidence suggests potential neuroprotective and organ-protective properties, although robust pediatric clinical data remains limited. Novel applications and alternative administration routes continue to expand the potential role of dexmedetomidine in pediatric practice. Overall, dexmedetomidine represents a versatile and valuable sedative agent in pediatric medicine, though further high-quality studies are needed to optimize dosing strategies and better define long-term safety outcomes.

  • Open Access

    GUT MICROBIOTA AND THE GUT–BRAIN AXIS IN ANXIETY DISORDERS: CURRENT EVIDENCE AND THERAPEUTIC PERSPECTIVES

    by Monika Sas-Wyżykowska, Anna Wyżykowska, Monika Maruszak, Michał Niedziela, Aliaksandr Kryshtofik, Alina Mykhalevych, Julia Grygorowicz, Gabriela Faria, Aleksandra Blachucik

    Anxiety disorders are among the most prevalent mental health conditions worldwide and constitute a significant public health challenge. Their pathogenesis is multifactorial and involves complex interactions between genetic, environmental, immunological, and neurobiological factors. In recent years, increasing attention has been directed toward the potential role of the gut microbiota and the gut–brain axis in the development and progression of anxiety disorders. The aim of this narrative review was to summarize current knowledge regarding the relationship between gut microbiota and anxiety disorders, with particular emphasis on the biological mechanisms underlying gut–brain communication and potential therapeutic implications. The review was based on scientific publications indexed in PubMed, Scopus, and Google Scholar databases, including preclinical studies, clinical trials, systematic reviews, and meta-analyses published mainly between 2010 and 2025. Available evidence indicates that gut microorganisms moderate central nervous system functioning through neural, immunological, endocrine, and metabolic pathways. Dysbiosis has been associated with altered stress responses, neuroinflammation, disturbances in neurotransmitter regulation, and hypothalamic–pituitary–adrenal axis dysfunction. Both animal and human studies suggest that alterations in gut microbiota composition may contribute to anxiety-related symptoms. Although microbiota-targeted interventions such as probiotics, prebiotics, dietary modifications, and fecal microbiota transplantation show promising results, current evidence remains insufficient for routine clinical implementation. Further well-designed clinical studies are necessary to clarify the role of gut microbiota in anxiety disorders and to evaluate the effectiveness of microbiota-based therapeutic strategies.

  • Open Access

    Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease

    by Aliaksandr Kryshtofik, Julia Grygorowicz, Gabriela Faria, Monika Sas-Wyżykowska, Alina Mykhalevych, Michał Niedziela, Monika Maruszak, Anna Wyżykowska, Aleksandra Blachucik, Akhil Roy Subramoney

    Background: Parkinson’s disease (PD) is the fastest-growing neurological disorder globally. Traditional diagnosis, which relies on motor symptoms, is associated with a 15–24% error rate and occurs after significant loss of dopaminergic neurons. Early biomarker identification is essential for biological redefinition of PD and timely intervention.Objective: To synthesize evidence from the past five years on minimally invasive biomarkers and assess whether multimodal panels offer greater diagnostic precision than single tests.Methods: A systematic review of PubMed and Scopus (January 2021–January 2026) was conducted per PRISMA guidelines, including meta-analyses and original studies on α-synuclein seed amplification assays (SAA), neuronally derived extracellular vesicles (LIEVs), neurofilament light chain (NfL), and advanced imaging (OCT-A, MRI).Results: SAA exhibited 96% sensitivity in GBA1 mutation carriers and 98.6% in hyposmic individuals with dopaminergic deficits, but only 67.5% in LRRK2 carriers. Serum LIEV-associated α-synuclein distinguished prodromal cases with high precision (AUC=0.91). NfL predicted functional decline (OR=2.54) up to five years before diagnosis. Advanced neuroimaging and skin RT-QuIC tests showed diagnostic accuracies from 82% to 100%.Conclusion: PD diagnosis is shifting from clinical observation to biological profiling. Multimodal biomarker panels integrating molecular, microvascular, and imaging data provide the most precise risk stratification, enabling timely, targeted neuroprotective interventions by rehabilitation specialists.

  • Open Access

    The Role of the Gut-Brain Axis in the Pathogenesis and Treatment of Irritable Bowel Syndrome in Children and Adolescents: A Review of Current Research with Focus on Dietary and Psychoneurogastroenterological Interventions

    by Julia Grygorowicz, Monika Maruszak, Anna Wyżykowska, Gabriela Faria, Alina Mykhalevych, Michał Niedziela, Monika Sas-Wyżykowska, Aliaksandr Kryshtofik, Aleksandra Blachucik

    Background. Irritable bowel syndrome (IBS) is a prevalent disorder of gut-brain interaction (DGBI) affecting 5-20% of children worldwide, with the microbiota-gut-brain axis (MGBA) playing a central pathophysiological role [7, 8, 21]. Aim. This narrative review evaluates MGBA-targeted therapeutic interventions in pediatric IBS. Materials and methods. A systematic search of PubMed/MEDLINE (2021-2025) following PRISMA guidelines identified 31 eligible studies from 45 initially screened articles. Results. Pediatric IBS pathophysiology involves intestinal dysmotility, visceral hypersensitivity, dysbiosis, and altered central processing of visceral signals [14, 15, 26]. The low-FODMAP diet has demonstrated efficacy in adults; however, pediatric evidence remains limited to five randomized trials with inconsistent results [25]. Probiotic supplementation with Lactobacillus rhamnosus GG and Limosilactobacillus reuteri DSM 17938 shows strain-specific efficacy [3, 4]. Cognitive-behavioral therapy and gut-directed hypnotherapy effectively target central signal processing [5, 21]. Pharmacological options, including neuromodulators, remain understudied in pediatric populations, with off-label use predominating [2, 12]. Psychological comorbidities, particularly anxiety and depression, significantly influence treatment response [1, 18]. Conclusions. The MGBA represents the primary therapeutic target in pediatric IBS, supporting multimodal approaches, but limitations in pediatric-specific evidence suggest the need for high-quality randomized controlled trials with standardized outcome measures and adequate long-term follow-up [6, 31].

  • Open Access

    DEPRESSION AND ANXIETY IN ADVANCED CANCER: DIAGNOSTIC AND THERAPEUTIC CHALLENGES IN PALLIATIVE CARE – A REVIEW

    by Anna Wyżykowska, Monika Maruszak, Julia Grygorowicz, Michał Niedziela, Gabriela Faria, Monika Sas-Wyżykowska, Alina Mykhalevych, Aliaksandr Kryshtofik, Aleksandra Blachucik

    Psychological distress, including depression and anxiety, represents a major clinical concern in patients with advanced cancer, particularly in palliative care settings, where it is associated with reduced quality of life, increased symptom severity, and impaired adherence to oncological treatment. The diagnosis of these conditions remains challenging due to the overlap between psychiatric and disease-related somatic symptoms, as well as the complex and multidimensional nature of distress in this population. This review examines key diagnostic challenges and current approaches to pharmacological management of depression and anxiety in advanced cancer, with particular emphasis on palliative care populations. The analysis is based on selected clinical guidelines and relevant clinical studies addressing both diagnostic and therapeutic aspects of care. Available evidence indicates that standard diagnostic criteria may have limited applicability in medically ill patients, requiring careful clinical interpretation and individualized assessment. Pharmacological treatment remains an important component of care, while symptom-oriented strategies and selected adjunctive agents may provide additional clinical benefit, and rapid-acting therapies represent a promising but still evolving area of research. Effective management requires a flexible, patient-centered approach that integrates clinical context, symptom profile, and treatment goals. Further research is needed to improve diagnostic strategies and to develop more effective and rapidly acting therapeutic options in palliative care settings.

  • DEEP BRAIN STIMULATION AS AN INNOVATIVE APPROACH IN THE TREATMENT OF NEUROLOGICAL DISORDERS – CURRENT INSIGHTS AND CLINICAL SIGNIFICANCE

    by Monika Maruszak, Michał Niedziela, Mateusz Chmiela, Julia Grygorowicz, Anna Wyżykowska

    Background The increasing life expectancy observed in recent decades has led to a growing prevalence of neurological disorders, creating a need for more effective therapeutic strategies. Deep Brain Stimulation (DBS), introduced in the late 20th century, has emerged as a promising neuromodulatory technique. Aim This study aims to summarize current knowledge on DBS and highlight its clinical applications in neurological disorders, particularly Parkinson's disease, epilepsy, and Alzheimer's disease. Methods A narrative review of published literature was conducted using PubMed and Google Scholar, covering publications through March 2026. Articles were selected based on clinical relevance and methodological quality; findings were synthesized descriptively. Results DBS has demonstrated significant efficacy in the management of drug-resistant neurological conditions, particularly Parkinson's disease and epilepsy. Emerging evidence suggests potential benefits in Alzheimer's disease, although findings remain inconclusive. Conclusions DBS represents an important therapeutic option for patients with refractory neurological disorders. Despite its established role in selected conditions, further research is required to better understand its mechanisms and expand its clinical indications.

  • Open Access

    Diagnostic Pitfalls, Creatine Supplementation, Physical Activity, and Kidney Function Assessment in Non-Dialysis Chronic Kidney Disease: A Narrative Review

    by Mateusz Chmiela, Anna Czesyk, Michał Słysz, Bartosz Krukowski, Ada Świątko, Michał Majewski, Magdalena Ząbczyńska, Weronika Ja, Monika Maruszak, Michał Niedziela

    Creatine supplementation is widely used by physically active people. In patients with non dialysis chronic kidney disease, it may complicate laboratory assessment of kidney function because serum creatinine reflects both glomerular filtration and creatinine generation. Creatine intake, muscle mass, diet, and physical activity may influence serum creatinine independently of true glomerular filtration rate. This narrative review discusses interpretation of kidney function markers in patients with non dialysis chronic kidney disease who use creatine supplementation, especially in the context of physical activity or resistance training. Creatine may increase serum creatinine without a parallel reduction in true glomerular filtration rate. Creatinine based equations may translate a non filtration related creatinine rise into a lower estimated glomerular filtration rate. Physical activity may add complexity because intense exercise, muscle injury, dehydration, or exertional rhabdomyolysis may also affect creatinine, creatine kinase, and kidney function markers. Supplement history and recent training load should be interpreted together with cystatin C, albuminuria, urinary sediment, biochemical abnormalities, and clinical status. Increased serum creatinine should be treated as a diagnostic ambiguity rather than automatically classified as kidney deterioration or benign artefact. Worsening cystatin C based estimated glomerular filtration rate, increasing albuminuria, active urinary sediment, biochemical abnormalities, oliguria, edema, hypertension, or signs of exercise related muscle injury should prompt evaluation for true kidney function deterioration.